Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract 6, "Sorafenib vs Placebo in Addition to Standard Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial," presented by Christoph Röllig, MD.
Laurie Sehn, MD, of the BC Cancer Agency, on abstract 289, “Nivolumab in Patients With Relapsed...
James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD of the Dana-Farber Cancer Institute, discuss three clinic...
Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 393,
Laurie Sehn, MD, of the BC Cancer Agency, on abstract 625, “Sustained Remission With the Combin...
Laurie Sehn, MD, on Lenalidomide Plus Rituximab in Previously Untreated Mantle Cell Lymphoma
Ayalew Tefferi, MD, of the Mayo Clinic, on abstract 403, “A Compendium of Cytogenetic Abnormali...